Leerink Partners analyst Michael Cherny reiterated a Market Perform rating and $41.00 price target on Hims and Hers (NYSE: HIMS).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

TD Cowen Reiterates Hold Rating on Hims and Hers (HIMS)February 6, 2026 6:04 AM Truist: 'Defending Lilly: LLY strong position helps guard their share in a crowded GLP-1 landscape'February 5, 2026 12:35 PM Wolfe Research on Eli Lilly (LLY): 'we question the legality of HIMS' ability to market an oral semaglutide'February 5, 2026 10:24 AM Wells Fargo on Eli Lilly (LLY): 'Compounders Strike Again, but We See Little Risk to Near-Term Growth'February 5, 2026 10:10 AM BMO Capital: 'Novo Mgmt Meetings Highlight Deep Strategic Challenges'February 5, 2026 9:58 AM Hims offers cheapest GLP-1 weight-loss pill in US in a shock to Novo, LillyFebruary 5, 2026 9:17 AM Hims stock surges as Wegovy pill copy offered at $49, Novo shares fallFebruary 5, 2026 9:08 AM Hims & Hers adds compounded semaglutide pills starting at $49 monthlyFebruary 5, 2026 9:01 AM Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*February 5, 2026 9:00 AM Hims & Hers Health (HIMS) launches a copy of Wegovy pill at $49/monthFebruary 5, 2026 8:31 AM Form 4 Hims & Hers Health, Inc. For: Feb 03 Filed by: Okupe OluyemiFebruary 4, 2026 4:13 PM HIMS launches multi-cancer screening blood test through GRAIL partnershipFebruary 4, 2026 9:07 AM Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive CareFebruary 4, 2026 9:00 AM